BioEvidence AI

Company: BioEvidence AI

Self-reported basis: The description is entirely self-reported and unverified, based on a Devpost submission for the OpenAI 2026 hackathon. No external corroboration or additional data exists.

What it appears to be: A tool that claims to validate single-cell marker data using AI, visualize results, and distinguish evidence from hypotheses — built as a prototype or proof-of-concept.

What changed: The project was submitted to a hackathon; no indication of prior development or commercial activity.

Most important open question: Is there any evidence of real-world use, customer feedback, or traction beyond the hackathon submission?

The description states that BioEvidence AI is "an evidence-aware AI assistant that validates single-cell marker data, visualizes results, and clearly separates direct evidence from hypotheses and unsupported claims."

• Claimed function: AI-assisted validation of single-cell marker data.
• Claimed output: Visualization of results.
• Claimed feature: Clear separation between evidence and hypotheses.

Evidence strength: Self-reported only. No demonstration, screenshots, or technical documentation provided.

The tagline positions the tool as an "evidence-aware AI assistant" for single-cell biology data. The author does not describe prior versions or positioning evolution — this is a first-time submission to a hackathon.

• Claimed value proposition: Ensures accuracy and clarity in scientific data interpretation.
• No evidence of prior claims or evolution.

Evidence strength: Self-reported, no historical context provided.

The description does not identify specific customer segments or personas. The focus on single-cell marker data suggests a scientific or research audience — likely biologists, bioinformaticians, or lab researchers.

• Inferred target: Researchers in life sciences or computational biology.
• No evidence of identified ICP.

Evidence strength: Inferred from domain; not evidenced.

There is no mention of pricing, monetization, or business model in the description.

• Claimed business model: Not stated.
• Pricing evidence: None provided.

Evidence strength: Not evidenced.

The author lists technologies used:

• Built with: api, git, github, gpt-5.6, numpy, openai, pandas, plotly, pydantic, pytest, python, streamlit
• Claimed tech stack: AI integration (GPT), data visualization (plotly), scientific computing (numpy, pandas), and UI (streamlit).

Evidence strength: Self-reported toolchain; no demonstration or delivery details.

The project was submitted to a hackathon — no evidence of prior traction, customers, or product maturity.

• No evidence of revenue, users, or adoption.
• No evidence of prior development or commercial use.

Evidence strength: Not evidenced.

There is no mention of competitors or market context in the description.

• No evidence of competitive landscape.
• No indication of existing tools for validating single-cell marker data.

Evidence strength: Not evidenced.

• Thin evidence base: Only a hackathon submission, no product, traction or validation.
• Unverified claims: No demonstration or third-party feedback.
• No business model: Unclear how the tool would be monetized or deployed.
• Single founder: No team structure or support beyond one person.

Evidence strength: Inferred from lack of evidence; not directly stated.

1. What is the validation process for single-cell marker data, and how does AI assist in that?
2. Is this a prototype or a working product?
3. Have you tested it with real scientific datasets or users?
4. What is your plan to move beyond the hackathon submission?
5. How do you intend to monetize or deploy this tool?